- Description
- Details
- Subprojects
- History
- Relations
- Publications
| Project Title: | Spore in lung cancer | |
| Principal Investigators (PI): |
BAYLIN STEPHEN B
|
|
| Project Number: | 5P50CA058184-13 | |
| Organization: | JOHNS HOPKINS UNIVERSITY | |
| Project Description: | ||
|---|---|---|
| The Johns Hopkins Lung Cancer SPORE is in its tenth year and continues to have as its goals, the performance of highly translational research to move ideas from the bench to bedside, and vice versa, to provide new means for the prevention of, risk assessment for, early detection of, gauging prognosis of, and therapy for, lung cancers of all types. In these efforts, extensive formal collaboration with other Lung Cancer SPORE'S is often emphasized. The program uses the flexibility of the SPORE funding mechanism to extend projects that continually evolve higher and higher translational potential and curtail those that do not. There is an emphasis on constantly bringing in new concepts and directions in parallel with fully evolving those areas that are headed for ultimate translational verification and even reaching common clinical practice. In terms of research at the highest translational level, including work at the population level, the SPORE is presently emphasizing the second and third projects (a collaborative venture with the Colorado SPORE), which are testing epigenetic molecular markers which appear to have very high promise for the areas of risk assessment, early detection, and gauging of prognosis of lung cancer. The first project, also aimed at predicting lung cancer risk and prognosis, is taking new approaches to develop genetic markers for these purposes. A fourth project is developing new concepts for lung cancer prevention by taking the concepts through pre-clinical models and initial proof of principle studies in high risk individuals. This work is very complementary with participation of the Hopkins SPORE in the consortium chemoprevention trials (Lung Cancer Biomarker Chemoprevention Consortium-LCBCC) with the other Lung Cancer SPORES and with a collaborative trial of Iloprost in collaboration with the Colorado SPORE. The fifth and sixth projects are both aimed at development of novel therapeutic strategies for lung cancer with one exploiting new insights into these diseases derived from study of molecular pathways guiding early lung development and the other exploring inhibition of fatty acid synthesis as a new approach. | ||
| Project Terms: | ||
| neoplasm /cancer chemotherapy neoplasm /cancer diagnosis | ||
| Project Title: | Spore in lung cancer | |
| Principal Investigators (PI): |
BAYLIN STEPHEN B
|
|
| Project Number: | 5P50CA058184-13 | |
| Organization: | JOHNS HOPKINS UNIVERSITY | |
| Project Categories: | ||
|---|---|---|
|
• Natural Sciences > Aging Diseases and Pathology > Cancer & related diseases > Malignant neoplasms (including in situ) > Lung cancer |
||
| Other Information: | ||
| Fiscal Year: | 1992 | |
| Project Start Date: | 30 September 1992 | |
| Project End Date: | 30 November 2008 | Administering Institute Or Center: | CA |
| Project Funding Information: | ||
| Total Funding: | $2,359,850 | |
| Year | Funding Organization | Total Funding, $ |
|---|---|---|
| 2007 | NATIONAL CANCER INSTITUTE | $2,359,850 |
| Project Title: | Spore in lung cancer | ||
| Principal Investigators (PI): |
BAYLIN STEPHEN B
|
||
| Project Number: | 5P50CA058184-13 | ||
| Organization: | JOHNS HOPKINS UNIVERSITY | ||
| Project_number | Title | Year | FY Total Cost |
|---|---|---|---|
| There are no results for this project in database. | |||
| Project Title: | Spore in lung cancer | ||
| Principal Investigators (PI): |
BAYLIN STEPHEN B
|
||
| Project Number: | 5P50CA058184-13 | ||
| Organization: | JOHNS HOPKINS UNIVERSITY | ||
| Project number | Project title | Principal investigator | |
|---|---|---|---|
| There are no any related projects. | |||
| Project Title: | Spore in lung cancer | |||
| Principal Investigators (PI): |
BAYLIN STEPHEN B
|
|||
| Project Number: | 5P50CA058184-13 | |||
| Organization: | JOHNS HOPKINS UNIVERSITY | |||
| Title | Abstract | Authors | Year | Rel |
|---|---|---|---|---|
| WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer. | Molecular biology of the cell. 2007 Nov 18 (11) :4292-303 | Yoshikawa, Hirohide; Matsubara, Kenichi; Zhou, Xiaoling; Okamura, Shu; Kubo, Takahiko; Murase, Yaeko; Shikauchi, Yuko; Esteller, Manel; Herman, James G; Wei Wang, Xin; Harris, Curtis C | 2007 |
 
|
| Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. | British journal of cancer. 2007 Mar 26 96 (6) :952-9 | Jimeno, A; Kulesza, P; Wheelhouse, J; Chan, A; Zhang, X; Kincaid, E; Chen, R; Clark, D P; Forastiere, A; Hidalgo, M | 2007 |
|
| Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. | Antioxidants & redox signaling. 2007 Nov 9 (11) :1963-70 | Thimmulappa, Rajesh K; Fuchs, Ralph J; Malhotra, Deepti; Scollick, Catherine; Traore, Kassim; Bream, Jay H; Trush, Michael A; Liby, Karen T; Sporn, Michael B; Kensler, Thomas W; Biswal, Shyam | 2007 |
|
| Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. | Annual review of pharmacology and toxicology. 2007 47 () :89-116 | Kensler, Thomas W; Wakabayashi, Nobunao; Biswal, Shyam | 2007 |
|
| Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. | Proceedings of the National Academy of Sciences of the United States of America. 2007 Mar 6 104 (10) :4048-53 | Peacock, Craig D; Wang, Qiuju; Gesell, Gregory S; Corcoran-Schwartz, Ian M; Jones, Evan; Kim, Jynho; Devereux, Wendy L; Rhodes, Jonathan T; Huff, Carol A; Beachy, Philip A; Watkins, D Neil; Matsui, William | 2007 |
|
| Selective inhibition of fatty acid synthase for lung cancer treatment. | Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Dec 1 13 (23) :7139-45 | Orita, Hajime; Coulter, Jonathan; Lemmon, Colleen; Tully, Ellen; Vadlamudi, Aravinda; Medghalchi, Susan M; Kuhajda, Francis P; Gabrielson, Edward | 2007 |
|
| FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer. | Pharmaceutical research. 2007 Jun 24 (6) :1202-7 | Lee, Jae Sung; Orita, Hajime; Gabrielson, Kathleen; Alvey, Sara; Hagemann, Ruth L; Kuhajda, Francis P; Gabrielson, Edward; Pomper, Martin G | 2007 |
|
| Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. | British journal of cancer. 2007 Apr 23 96 (8) :1278-83 | Belinsky, S A; Grimes, M J; Casas, E; Stidley, C A; Franklin, W A; Bocklage, T J; Johnson, D H; Schiller, J H | 2007 |
|
| LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. | Cancer research. 2007 May 1 67 (9) :4123-9 | Wu, Guojun; Guo, Zhongmin; Chang, Xiaofei; Kim, Myoung Sook; Nagpal, Jatin K; Liu, Junwei; Maki, Joni M; Kivirikko, Kari I; Ethier, Stephen P; Trink, Barry; Sidransky, David | 2007 |
|
